Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant

The RV144 Phase III clinical trial with ALVAC-HIV prime and AIDSVAX B/E subtypes CRF01_AE (A244) and B (MN) gp120 boost vaccine regime in Thailand provided a foundation for the future development of improved vaccine strategies that may afford protection against the human immunodeficiency virus type...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Yingxia, Trinh, Hung V., Linton, Christine E., Tani, Chiara, Norais, Nathalie, Martinez-Guzman, DeeAnn, Ramesh, Priyanka, Sun, Yide, Situ, Frank, Karaca-Griffin, Selen, Hamlin, Christopher, Onkar, Sayali, Tian, Sai, Hilt, Susan, Malyala, Padma, Lodaya, Rushit, Li, Ning, Otten, Gillis, Palladino, Giuseppe, Friedrich, Kristian, Aggarwal, Yukti, LaBranche, Celia, Duffy, Ryan, Shen, Xiaoying, Tomaras, Georgia D., Montefiori, David C., Fulp, William, Gottardo, Raphael, Burke, Brian, Ulmer, Jeffrey B., Zolla-Pazner, Susan, Liao, Hua-Xin, Haynes, Barton F., Michael, Nelson L., Kim, Jerome H., Rao, Mangala, O’Connell, Robert J., Carfi, Andrea, Barnett, Susan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919662/
https://www.ncbi.nlm.nih.gov/pubmed/29698406
http://dx.doi.org/10.1371/journal.pone.0194266

Ejemplares similares

Ejemplares similares